Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 3-year-old boy diagnosed with temporal triangular alopecia, emphasizing the importance of clinical and dermoscopic examination for correct diagnosis due to the condition's rarity and risk of misdiagnosis.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

This study developed a new, simple, and economical RP-TLC method with densitometry that is suitable for routine analysis of finasteride in tablet dosage form, meeting analytical validation criteria.

This study found that iron deficiency anemia is a key factor in the development of telogen effluvium, and higher 25-hydroxyvitamin D3 levels in TE patients may be linked to increased UV exposure.

This study investigated improving Finasteride's water solubility using trimethyl-β-cyclodextrin (TM-β-CD) and β-cyclodextrin (β-CD) as carriers, finding that β-CD improved Fin's cumulative release, while TM-β-CD enhanced its solubility, with computational data supporting these outcomes.

In this study, telogen effluvium is characterized as a common condition in women involving sudden hair shedding due to hair follicles prematurely entering the telogen phase, with potential triggers including fever, childbirth, and stress.

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

In this study, tazarotene 0.1% gel showed greater efficacy than tretinoin 0.025% gel in reducing acne lesions and demonstrated similar efficacy to adapalene 0.1% gel when used less frequently.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Vitamin D deficiency is common in temporary hair loss, and stress is often a suspected cause.

This article discusses telogen effluvium as a common cause of temporary hair loss due to disruptions in the hair growth cycle and notes that new hair continues to grow.

The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.

This study suggests that Terminalia chebula fruit extract may promote hair growth in androgenetic alopecia by activating specific signaling pathways and inhibiting 5α-reductase, showing effectiveness comparable to finasteride.

Telogen effluvium is a condition that causes temporary hair loss due to stress or shock to the body.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

In this study, researchers found that specific treatment parameters disrupted follicles and sebaceous glands, damaging the bacteria Cutibacterium acnes and promoting follicular remodeling, which may improve both inflammatory and noninflammatory acne lesions.

Tremella fuciformis Berk helps protect hair from stress-related damage.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

This case report describes a patient with eruptive tumor of follicular infundibulum, emphasizing the need for dermatologists to include it in the differential diagnosis of acquired facial hypopigmentation.

This review covers the current procedure for follicular unit hair transplantation, noting that recent advancements have made the results natural and undetectable, but it presents no new experimental findings.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.